-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On June 15th, the Center for Drug Evaluation (CDE) of the National Food and Drug Administration of China announced that the aripiprazole oral solution of Sichuan Otsuka Pharmaceutical Co.
, Ltd.
, a subsidiary of Otsuka Pharmaceutical, is suitable for children’s use.
The new varieties, dosage forms and specifications of drugs have been included in the priority review by CDE.
The proposed indications are: irritable symptoms of autism in children and adolescents aged 6-17 years; Tourette syndrome in children and adolescents aged 6-17 years
.
Screenshot source: CDE official website
The aripiprazole oral solution of Sichuan Otsuka Pharmaceutical Co.
, Ltd.
is planned to be included in the priority review.
The proposed indications include autism irritable symptoms and Tourette syndrome
.
According to the Chinese drug clinical trial registration and information disclosure platform, the product has previously completed a multi-center, randomized double-blind, variable-dose, placebo-controlled, phase 3 treatment for children and adolescents with autism in China.